http://rdf.ncbi.nlm.nih.gov/pubchem/patent/ES-2441177-T3
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_1f85af810578fac3d697eb58690a6f7c |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-70571 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K7-64 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-705 |
| filingDate | 2006-03-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2014-02-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2552a69c398913ef7cee95169fcfb591 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0a77a4af6d01c2c0051f49a6c7a87cb4 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a1acb701543df18416ba34c8840dd837 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9d272f4c49e0406d6f3670fea203ece8 |
| publicationDate | 2014-02-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | ES-2441177-T3 |
| titleOfInvention | Means for inhibition of anti-1-adrenergic receptor antibodies |
| abstract | Peptide selected from the group consisting of a) a cyclic peptide of formula Ib: Cycle (Ala-x2-x4-x1-x4-x1-x1-x4-x2-x2-Cys-x3-x5-x1-Pro-x2- Cys-Cys-x1-x3-x3-x4-x5-x2-Gln) (Ib) in which x1 is selected individually and independently from the group comprising acidic amino acids; x2 is selected individually and independently from the group comprising basic amino acids; x3 is selected individually and independently from the group comprising Leu, Ile, Val, Met, Trp, Tyr and Phe; x4 is selected individually and independently from the group comprising Ser, Thr, Ala and Gly; and x5 is selected individually and independently from the group comprising Gln and Asn; and b) a cyclic peptide of formula IIIa: Cycle (Ala-x4-x2-x3-x1-x3-x3-x4-x3-x3-Cys-xj-Cys-xxx-Pro-x-Cys-Cys-xi-Gln ) (IIIa) in which i is any integer from 0 to 6, preferably any integer from 1 to 6, more preferably i> = 6; wherein j is any integer from 0 to 4, preferably any integer from 1 to 4, more preferably j> = 4; wherein x1 is selected individually and independently from the group comprising amino acid; x2 is selected individually and independently from the group comprising basic amino acids; x3 is selected individually and independently from the group comprising Leu, Ile, Val, Met, Trp, Tyr and Phe; and x4 is selected individually and independently from the group comprising Ser, Thr, Ala and Gly, in which x is any amino acid, preferably any naturally occurring amino acid, more preferably any naturally occurring L-amino acid, and where said peptide is capable of acting as an inhibitor of β1-adrenergic receptor antibodies. |
| priorityDate | 2005-03-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 168.